At the 2023 Bio-Europe Spring, RudaCure was representó by CEO Yongho Kim and Research Strategy Team Leader Hawon Jeon, who held a meeting with Ceva, a French company currently exploring codesarrollo of RCI001 for medicina veterinaria.
The meeting proporcionó an opportunity to discuss future joint comercialización directions with Ceva representatives and to exchange information that both empresas need to share.
Many empresas showed interest in RCI001 for enfermedad de ojo seco and productive discussions were held. For RCI002, the tratamiento del dolor, Italian company Dompe and the long-establecido German company Grünenthal expresó interest and agreed to continue discussions on the drug.
